FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... October 20, 2025 Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... August 17, 2020 SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... July 27, 2023 Load more HOT NEWS A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause... Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for... Despite Proven Safety of HPV Vaccines, More Parents Have Concerns
